RECIST, Response Evaluation Criteria in Solid Tumors, was developed for use in clinical trials with a primary endpoint of objective response.
Criteria for DLT/MTD recommended dose for phase I for non cytotoxic agents
Meta-analysis intended to qualify durable complete response as a surrogate endpoint for progression-free survival in follicular lymphoma. EORTC trial 20921
Discussions underway for a project to validate relapse-free survival as a surrogate to overall in adjuvant melanoma.
EORTC is a major participant to the Innovative Medicine Initiative (IMI) being involved in programs such as PharmaTrain, being the managing entity of QuIC-ConCePT, an imaging program aiming at the qualification and validation of biomarkers, and Eupati, a patient initiative.